Novel Lipid Nanoparticle Delivery Reagent And Rapid Manufacturing Workflow To Accelerate Preclinical Development Of RNA Vaccines
Source: Precision NanoSystems
The biggest vaccine campaign in history is ongoing against COVID-19, with RNA vaccines playing a key role. Due to the rapid degradation of RNA and low cellular uptake, an essential element of RNA vaccines are lipid nanoparticle (LNP) delivery systems. Limited access to ionizable lipids and LNP compositions, and the difficulty in scale-up production of RNA-LNPs remain challenges in the field. In this study, we aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.
access the Poster!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Precision NanoSystems
This website uses cookies to ensure you get the best experience on our website. Learn more